Concise review: making and using clinically compliant pluripotent stem cell lines.

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Stem Cell Biology

Background:

• Pluripotent stem cells (PSCs) are advancing rapidly, with new methods for derivation and generation.
• Companies are preparing for clinical trials using human PSC derivatives under Good Manufacturing Practice (GMP).

Purpose of the Study:

• To review the challenges in manufacturing, storing, and distributing PSC-derived biological products.
• To discuss regulatory and cost barriers for PSC-based cell therapies.
• To present a model for cost reduction and innovation in PSC research.

Main Methods:

• Review of current advances in PSC derivation and manufacturing.
• Analysis of challenges in tissue sourcing, production, storage, and distribution.
• Description of a proposed National Institutes of Health (NIH) model for cost reduction and flexibility.

Main Results:

• Significant technological advances are driving the field of PSCs.
• Manufacturing, regulatory, and cost challenges impede clinical translation.
• A proposed NIH model offers a framework for cost reduction and innovation.

Conclusions:

• Addressing manufacturing and regulatory challenges is crucial for PSC-based cell therapy.
• The NIH model, with regulatory adjustments, can accelerate the implementation of PSC therapies.
• Optimizing production and regulatory pathways is key to realizing the potential of PSCs.